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Introduction
Most cancer-related mortality is due to distant meta-
stases. Metastasis is a multistep process whereby cells 
from the primary tumor invade or migrate through 
surrounding tissues and barrier matrices, disseminate via 
the vasculature (hematologic or lymphatic), arrest and 
extravasate at the metastatic niche, and ultimately survive 
and outgrow in this ectopic environment. Ectopic-site 
survival and subsequent proliferative outgrowth is the 
rate-limiting step in clinically evident disease [1,2]. 
Distant metastases are generally more resistant to 
treatments than the primary tumor [3], underscoring the 
need to develop more rational therapeutic approaches 
based on the molecular pathophysiology in the metastatic 
microenvironment [4].
Clinically undetectable metastases have serious impli-
cations for cancer patients; approximately one-third of 
women suﬀ ered a metastatic relapse within 5 years post 
lumpectomy [5,6]. Th is late emergence implies that 
tumor cells disseminate early and survive undetected in 
ectopic sites [5,6]. Numerous three-dimensional models 
of tumor cells capture a subset of tumor behaviors [7-11]. 
A signiﬁ cant gap exists in investigating how metastatic 
nodules interact with the host tissue due to the inherent 
small-scale dimensions of most microﬂ uidic devices, 
poor disease recapitulation by cell lines, and lack of a 
primary cell environment. Th ere is an urgent need for 
integrated in vitro systems that can support the initial 
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micrometastatic nodules [12] to develop rational 
approaches to target growing cancer cells and promote 
clinically undetectable micrometastases towards a 
dormant state [13]. Th is process occurs over days to 
weeks and current endpoint analyses provide correlative, 
not mechanistic, insights and are mainly limited to 
carcinoma cell behavior. Th e microphysiological system 
proposed is evaluable over weeks, and is comprised of all 
human modiﬁ able components with programmable 
inputs of modiﬁ ers that allow deﬁ nition of the required 
signals for the microenvironment.
Th e liver as a target tissue is ideal because it is a 
preferred site of metastasis for many tumors (breast, 
lung, colon, prostate, brain, melanomas). Th e liver is also 
the major organ for drug metabolism (both activation 
and detoxiﬁ cation), a signiﬁ cant factor in determining 
eﬃ  cacy and limiting toxicities in cancer therapeutics. 
Hepatic tissue can thus be used to develop and determine 
the eﬃ  cacy of anticancer agents and regimens [12,14]. 
Th e liver is also one of the primary sites of systemic 
regulation of nutrients and hormones associated with 
circadian rhythms and immune system function. Th ese 
nutrients, hormones, and modulators impact the 
metabolic functioning of the liver and the responsiveness 
of tumor cells [15,16]. Chronic disruption of circadian 
rhythms is correlated with changes in immune regulators 
[17,18], and reductions in nutrients may provide better 
tolerance of high-dose chemotherapy [19]. Although 
toxicity of some chemotherapeutic agents is linked to 
circadian timing of delivery in patients [20], it is unknown 
whether chronobiological dosing is more eﬀ ective in 
treating micrometastases due to inability to detect these 
small tumors in the clinical setting. A large gap exists in 
linking the complex metastatic microenvironment to 
molecular signals that change on a diurnal basis at both 
systemic and local levels [21-23]. Th is model will yield 
markers of metastatic behavior that enable better clinical 
monitoring, and will guide the design of clinical studies 
to understand eﬃ  cacy.
Technology for this work
Platform
Th e perfused microreactor system (LiverChip; Zyoxel Ltd, 
Oxford, UK) we are using allows for tissues with high-level 
structural organization, functional complexity, ease of use, 
adequate samples for assays and weeks of culture while 
avoiding materials that adsorb steroid hormones and drugs 
[24]. Th is project dovetails with a parallel eﬀ ort on a 
DARPA (Defense Advanced Research Projects Agency 
(USA))-funded Microphysiological Systems program (PI: L 
Griﬃ  th, MIT), where a ﬂ uidic circuit is being applied to a 
broader platform of 10 diﬀ erent integrated micro physio-
logical systems on a platform, enabling the study of gut/
liver eﬀ ects on metastases.
To achieve temporal control of medium components, 
we invoke inlet micropumps to dose insulin/glucagon, 
glucose/fructose, cortisol, and chemotherapeutics into 
the reactor in tandem with a ﬂ uid control system that 
infuses fresh basal medium and removes waste. Bio-
reactors are also instrumented with oxygen measurement 
systems based on ruthenium microprobes. Th is highly 
instrumented three-dimensional culture format hosting a 
growing tumor and monitoring its responses is readily 
transferable to other organs.
Cells
Fresh human hepatocytes and a full complement of 
nonparenchymal cells oﬀ er the ability to evaluate the role 
of the diverse populations in the metastatic tumor micro-
environment in an all-human system. Cryopreserved 
hepatocytes and Kuppfer cells are also evaluated. To 
study metastatic nodules in the liver we use represen-
tative breast cancer cell lines (MDA MB 231, MCF-7, and 
BT474), control epithelial cells (human mammary epi the-
lial cells), as well as primary breast carcinoma explants. 
Th ese cell sources allow us to closely model the meta-
static niche of the liver in an unprecedented manner.
Modeling
Prediction of disease phenotypes and therapeutic eﬀ ects 
based on genomic variation has proved elusive. To under-
stand how the deregulation of cellular networks underlies 
complex disease states, such as cancer, an alternative 
systems-based approach will elucidate cellular responses 
to external stimuli. Predictive mathematical models are 
constructed by introducing the system (that is, cells) to 
perturbations or cues, which result in multiple cell states. 
Phenotypic responses are measured, enabling quantita-
tive, multivariate computational models to evaluate how 
cells will respond to new combinations of cues [25,26]. 
From a systems biology perspective, signaling networks 
are identiﬁ ed that in turn facilitate the evaluation of 
therapeutic targets and modulate systemic eﬀ ects [27,28]. 
Methods of multivariate analyses allow the integration of 
complex data (for example, cytokines, chemokines, and 
growth factors, acute phase proteins, and metabolites) 
resulting from the growth of small metastatic nodules, 
both to glean possible signatures of early metastatic 
disease and response to therapies as well as to identify 
therapeutic targets.
Key questions addressed
Do diurnal changes within host liver tissue alter the 
phenotypic behavior of the tumor cells compared with 
standard culture?
Noninvasive measurements (capabilities noted in Figure 1) 
that reveal information about the evolution of cell signal-
ing networks, coupled with appropriate computa tional 
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analysis, will provide a foundation for comparison with 
clinical observations. We previously demonstrated E-
cadherin coupling between carcinoma cells and hepato-
cytes, and continued uncontrolled growth of other cancer 
cells in the population [12,14]. Th e latter phenomenon 
may arise from stimulation of insulin-like growth factor-1 
receptor by the supraphysiological concen trations of 
insulin in standard hepatocellular cultures or the 
inﬂ ammatory cytokines due to matrix stiﬀ ening, or even 
the matrix stiﬀ ness itself. Diurnal control of nutrients 
and hormones will aﬀ ect both the cancer cell and host 
tissue phenotypes to give rise to both macroscopic and 
molecular behaviors that are diﬀ erent from those 
observed in standard culture (Figure  1). An attenuated 
growth pattern in diurnal control cultures compared with 
standard culture may reﬂ ect a more physiological 
condition (metastatic dormancy) that will be related to 
experimentally testable mechanisms (for example, 
diﬀ erences in the activation of insulin-like growth 
factor-1 receptor). Simultaneously sampling oxygen, 
metabolic, and cytokine measurements will yield insights 
that include crosstalk between tumor and host tissue, 
early markers of drug eﬃ  cacy and toxicity, and 
therapeutic targets.
Do chemotherapeutic toxicological eff ects on liver 
parallel clinically reported toxicological eff ects? Is 
effi  cacy of chemotherapy agents against metastatic 
tumors infl uenced by diurnal control of metabolism and 
hormones?
Hepatotoxicity of ﬁ rst-line, nontargeted chemotherapy 
agents (doxorubicin, carboplatin, and so forth) and newer 
targeted drugs (lapatinib) is well known and managed 
clinically due to their eﬃ  cacy in primary cancer 
treatment. Th e liver bioreactor intimately links tumor 
eﬃ  cacy with hepatic metabolism of the agent allowing 
for the identiﬁ cation of drug combinations that may 
exhibit synergistic or antagonistic eﬀ ects that are diﬃ  cult 
to identify in preclinical trials. Metastases likely alter 
metabolism of chemotherapeutics by hepatocyte crowd-
ing and loss as well as by the signals produced by the 
cancer cells themselves [29]. Th ese reciprocal paracrine 
Figure 1. Micrometastasis progression in standard and diurnal cultures. Conceptual view of (top) micrometastasis progression in three-
dimensional perfused liver microreactors maintained with controlled circadian profi les of key components of the portal circulation (nutrients, 
insulin) and the systemic circulation (cortisol) compared with (bottom) micrometastasis progression in standard culture with daily medium 
changes. Approximate relative values of diurnal fl uctuations in the tissue microenvironment are shown for each case; absolute magnitudes of 
cortisol and insulin are conventionally supraphysiological in the standard culture. Micrometastases are created by seeding individual tumor 
cells within the parenchyma of the tissue mimic, where fl ow of oxygenated culture medium into the tissue supports survival and proliferation. 
Carcinoma cells may re-express cadherin and integrate into the tissue, or may exhibit unrestrained growth. As tumors grow, the tissue becomes 
hypoxic, stromal cells proliferate, and the mix of cytokines and acute phase proteins becomes altered. Parameters listed (nutrient and hormone 
levels, cytokine levels, oxygen) are measured noninvasively to assess the progression of metastases. A premise is that the uncontrolled metastases 
stimulated by supraphysiological levels of hormones and nutrients in standard culture will be easier to eradicate by traditional chemotherapeutic 
agents that target proliferation, and thus fail to represent the full spectrum of behaviors of clinically important metastases compared with the case 
of controlled diurnal stimulation. PO2, oxygen partial pressure.
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eﬀ ects likely alter both eﬃ  cacy and toxicity/detoxi ﬁ cation 
and are further inﬂ uenced by diurnal changes in the 
bioactive hormones and nutrients that feed into the liver.
Do mild infl ammatory states of liver stimulate tumor 
growth and alter effi  cacy of chemotherapeutics?
Th e mechanisms for metastatic dormancy and emergence 
remain unknown but a proposed explanation is that 
inﬂ ammatory cytokines and matrix components drive 
the cancer cells into a proliferative state [5]. Inﬂ ammation 
in the liver can come from in situ insult or portal 
circulation that has bacterial inﬂ ammatory initiators 
from the gut microbiome (among others). In the assess-
ment of how inﬂ ammatory cues aﬀ ect the tumor 
response we will use lipopolysaccharide as a cue [30] at 
low chronic doses, challenge the tissue with chemo-
therapy, and integrate these data into our systems biology 
models. We can then explore gut–liver interactions 
directly on our microphysiologic systems platform. Th e 
chemoresponsiveness is unpredicatable because the 
greater proliferative fraction should increase chemo-
therapy sensitivity while the inﬂ ammatory milieu should 
promote resistance, making this model vital for better 
understanding of metastatic disease therapies.
Future needs and research directions
From this work we anticipate eﬀ ective solutions to 
augment the existing cell culture models throughout the 
drug development pipeline – target identiﬁ cation, valida-
tion, preclinical eﬃ  cacy, and safety – and shift substantial 
risk from human clinical trials back to the preclinical 
development stage. We focus on occult metastases as 
these represent substantial challenges in preclinical 
development due to the complexities of identifying such 
nodules and monitoring their response to therapies in 
the clinic. We anticipate linking this model to other 
physiological systems (intestine, cardiovascular, pan-
creatic) that both regulate and are regulated by the liver 
to frontload the risk from human and animal subjects to 
in vitro systems. Additionally we envision that this 
platform can have substantial impact on the study of the 
mechanisms inﬂ uencing breast cancer metastatic dor-
mancy, emergence, proliferation and chemo responsive-
ness under heretofore elusive conditions. Th is robust in 
vitro model in conjunction with systems biology will 
better predict disease response to new combinations of 
cues and treatments allowing for the identiﬁ cation and 
testing of eﬀ ective therapeutic targets.
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